Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit® Technology to Enable Gene Editing in Rett Syndrome

OXFORD, United Kingdom, February 26, 2026 — Evox Therapeutics Ltd (“Evox” or the “Company”), a biotechnology company developing innovative therapies for genetically driven neurodegenerative diseases using a next-generation gene editing modality, today announced it is initiating a collaboration with the Rett Syndrome Research Trust (RSRT) to assess the feasibility of using the Company’s ExoEdit® exosome-based … Read more The post Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit® Technology to Enable Gene Editing in Rett Syndrome appeared first on Evox Therapeut